Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $41.9 million.

  • Anika Therapeutics' Total Non-Current Liabilities fell 1747.12% to $41.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.9 million, marking a year-over-year decrease of 1747.12%. This contributed to the annual value of $48.0 million for FY2024, which is 1722.48% down from last year.
  • As of Q3 2025, Anika Therapeutics' Total Non-Current Liabilities stood at $41.9 million, which was down 1747.12% from $39.3 million recorded in Q2 2025.
  • Anika Therapeutics' Total Non-Current Liabilities' 5-year high stood at $79.8 million during Q1 2021, with a 5-year trough of $39.3 million in Q2 2025.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $57.3 million (2023), whereas its average is $56.2 million.
  • The largest annual percentage gain for Anika Therapeutics' Total Non-Current Liabilities in the last 5 years was 2288.67% (2021), contrasted with its biggest fall of 4833.29% (2021).
  • Quarter analysis of 5 years shows Anika Therapeutics' Total Non-Current Liabilities stood at $59.2 million in 2021, then grew by 6.72% to $63.2 million in 2022, then decreased by 8.24% to $58.0 million in 2023, then dropped by 17.22% to $48.0 million in 2024, then fell by 12.73% to $41.9 million in 2025.
  • Its last three reported values are $41.9 million in Q3 2025, $39.3 million for Q2 2025, and $41.5 million during Q1 2025.